Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PDP1 is a key metabolic gatekeeper and modulator of drug resistance in FLT3-ITD-positive acute myeloid leukemia.

Leukemia - 1 Dec 2023

Alshamleh Islam, Kurrle Nina, Makowka Philipp, Bhayadia Raj, Kumar Rahul, Süsser Sebastian, Seibert Marcel, Ludig Damian, Wolf Sebastian, Koschade Sebastian E, Stoschek Karoline, Kreitz Johanna, Fuhrmann Dominik C, Toenges Rosa, Notaro Marco, Comoglio Federico, Schuringa Jan Jacob, Berg Tobias, Brüne Bernhard, Krause Daniela S, Klusmann Jan-Henning, Oellerich Thomas, Schnütgen Frank, Schwalbe Harald, Serve Hubert

Abstract excerpt

High metabolic flexibility is pivotal for the persistence and therapy resistance of acute myeloid leukemia (AML). In 20-30% of AML patients, activating mutations of FLT3, specifically FLT3-ITD, are key therapeutic targets. Here, we investigated the influence of FLT3-ITD on AML metabolism. Nuclear Magnetic Resonance (NMR) profiling showed enhanced reshuffling of pyruvate towards the tricarboxylic acid (TCA) cycle,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to fms-Like Tyrosine Kinase 3

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Pyruvates

Source

Open in PubMed Open full text

Identifiers

PMID: 37935978
DOI: 10.1038/s41375-023-02041-5
PMCID: PMC10681906

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PDP1 is a key metabolic gatekeeper and modulator of drug resistance in FLT3-ITD-positive acute myeloid leukemia.PMID 37935978Read ↗

The Glycolytic Gatekeeper PDK1 defines different metabolic states between genetically distinct subtypes of human acute myeloid leukemia.Semantic proximity Read ↗

Exploiting metabolic vulnerabilities for personalized therapy in acute myeloid leukemiaSemantic proximity Read ↗

Rationale for Targeting Deregulated Metabolic Pathways as a Therapeutic Strategy in Acute Myeloid LeukemiaSemantic proximity Read ↗

Inhibition of the succinyl dehydrogenase complex in acute myeloid leukemia leads to a lactate-fuelled respiratory metabolic vulnerability.Semantic proximity Read ↗

Glutaminolysis is a metabolic dependency in FLT3ITD acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition.Semantic proximity Read ↗

Quizartinib-induced resistance drives clonal emergence of MV4-11 cells with molecular alterations enabling multidrug antileukemic escape.Semantic proximity Read ↗

A metabolic synthetic lethality of phosphoinositide 3-kinase-driven cancerSemantic proximity Read ↗

Mechanisms of T‑cell metabolic reprogramming in the microenvironment of acute myeloid leukemia and its therapeutic potential (Review)Semantic proximity Read ↗

Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia.Semantic proximity Read ↗

The HNRNPC/CELF2 signaling pathway drives glycolytic reprogramming and mitochondrial dysfunction in drug-resistant acute myeloid leukemiaSemantic proximity Read ↗

Combinatory therapy targeting mitochondrial oxidative phosphorylation improves efficacy of IDH mutant inhibitors in acute myeloid leukemiaSemantic proximity Read ↗

Quizartinib and omacetaxine mepesuccinate combination therapy in FLT3-ITD AML: a phase II trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.